Better Therapeutic Outcomes for Atopic Dermatitis Patients Guided by Gene Expression Profiling

Main Article Content

Marcia J. Glenn, MD
Amanda Caldwell, FNP-C
Valerie Cooper, PA-C, MPAS
Vivian Hunt, APRN, DCNP
Chioma Okpala, BSc.

Keywords

Atopic dermatitis, biologic therapies, JAK inhibitor, 487-GEP, gene expression profiling

References

1. Eczema facts and statistics. National Eczema Association. Accessed November 15, 2025.

2. Castle Biosciences reports preliminary data from atopic dermatitis test study. Medical Device Network. December 2024.

3. CADTH Cost-Comparison Table for Moderate-to-Severe Atopic Dermatitis. NCBI Bookshelf. Accessed November 15, 2025.

4. Mehrmal S, Tan MG, Arron ST, et al. Gene Expression Profiling (GEP) in Dermatology, Part 1: Introduction, Development, Benefits, Limitations, and Future Directions. Journal of the American Academy of Dermatology. 2025.

5. Farberg A, Hebebrand M. Explains Gene Profiling in Atopic Dermatitis. Dermatology Times. October 2025.

6. Silverberg JI, Eichenfield LF, Armstrong A, et al. The 487-Gene Expression Profile Test Guides Systemic Therapy Selection to Improve Outcomes for Patients with Atopic Dermatitis: Results from a Prospective, Multi-Center Trial. SKIN The Journal of Cutaneous Medicine. 2025;9(6):s621.

7. 487-GEP Test Identifies Optimal Systemic Therapy for AD. Practical Dermatology. October 2025.

Article Sidebar

PDF
Published
2026-01-13
DOI: https://doi.org/10.25251/5mck0k94

Article Details

How to Cite
1.
Better Therapeutic Outcomes for Atopic Dermatitis Patients Guided by Gene Expression Profiling. J of Skin. 2026;10(1):2949-2951. doi:10.25251/5mck0k94
Issue
Vol. 10 No. 1 (2026): January 2026 Issue
Section
Editorials
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)